Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000250836 | SCV000311815 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV000675856 | SCV001724125 | benign | not provided | 2025-02-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000675856 | SCV001755755 | benign | not provided | 2015-03-03 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001660303 | SCV001875626 | benign | Encephalopathy, lethal, due to defective mitochondrial peroxisomal fission 1 | 2021-07-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001660304 | SCV001875627 | benign | Optic atrophy 5 | 2021-07-30 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000250836 | SCV004848617 | benign | not specified | 2022-02-04 | criteria provided, single submitter | clinical testing | The p.Ser40Ser variant in DNM1L is classified as benign because it has been identified in 12.4% of total chromosomes in gnomAD, including 2316 homozygous individuals (https://gnomad.broadinstitute.org/). |
Breakthrough Genomics, |
RCV000675856 | SCV005229899 | benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000675856 | SCV000801579 | benign | not provided | 2016-02-22 | no assertion criteria provided | clinical testing |